Nitrones: not only extraordinary spin traps, but also good nitric oxide sources in vivo by MIRCEA DUMITRU CROITORU et al.
413
Acta Pharm. 65 (2015) 413–426 Original research paper
DOI: 10.1515/acph-2015-0032
Nitrones: not only extraordinary spin traps, 
but also good nitric oxide sources in vivo
Free radicals are involved in the development of reperfu-
sion injuries. Using a spin trap, the intensity of such lesions 
can be reduced. Nitrones (effective in vivo spin traps) were 
tried in this work as in vivo nitric oxide donors. Nitrite and 
nitrate concentration values (rabbit blood) were used as bio-
markers of nitric oxide production. Most nitrones did not 
increase plasma concentrations of nitrite and nitrate; on the 
contrary, reduced plasma concentrations of these indica-
tors were noted. However, glyoxal isopropyldinitrone, in a 
dose of 50 mg kg–1, was highly effective in increasing nitric 
oxide production. At the same time, nitrones do not react 
with hepatic homogenates, proving that the release of nitric 
oxide takes place in the tissues and is not related to hepatic 
metabolism. Before using nitrones in vivo, they were tested 
in vitro for the ability to release nitric oxide following a re-
action with the hydroxyl radical.
Keywords: nitric oxide, nitrite, nitrate, nitrones, nitric oxide 
donor
When blood and nutrient flow is reduced in a tissue, ischemic diseases appear. During 
the ischemic period, tissue metabolism slows down, followed by over-active metabolic 
processes soon after the blood and nutrient flow is re-established, leading to generation of 
high quantities of free radicals. This excess of free radicals, both by apoptotic and necrotic 
pathways, has been proven to have a major impact on the development of reperfusion in-
juries (1, 2). The most common forms of free radicals are superoxide anion, hydroxyl radi-
cal, carbon-centered radicals, nitric oxide and nitrogen dioxide. Peroxynitrite and hydro-
gen peroxide, which are not free radicals themselves, can become important sources of free 
radicals (centered on oxygen and nitrogen) by electron accepting processes. The hydroxyl 
radical, considered to be the most damaging radical in cells, is extensively generated dur-
ing ischemia and reperfusion by the Fenton reaction and decomposition of peroxynitrite 
at low pH, inducing cell membrane damage, a necrotic process, by peroxidation of unsatu-
rated fatty acids. Superoxide anion causes mitochondrial membrane dysfunction and leads 
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peroxide increases the influx mode activity of the Na+/ca2+ exchanger, suggesting that 
oxidative stress might be involved in the ca2+ overload, a key factor in the development of 
reperfusion injuries (4). the most affected organs by ischemia/reperfusion injuries are the 
myocardium and the brain.
there are several methods attempting to reduce the intensity of these lesions: (i) in-
creasing the antioxidant defense systems and the amount of cell survival proteins by isch-
emic and remote ischemic preconditioning (5), (ii) inducing the reperfusion injury salvage 
kinase (riSk) pathway which, when activated specifically at the time of myocardial reper-
fusion, confers powerful cardioprotection (6), (iii) using naturally occurring spin traps, 
such as vitamin C, vitamin e, and polyunsaturated fatty acids for reduction of excessive 
superoxide anion production and protection of cardiac tissues from oxidative damage 
during heart surgery with extracorporeal circulation (7, 8).
these methods, proven effective in some studies, are designed for cardioprotection 
during heart surgery when the heart is stopped and restarted after an ischemic period. 
unfortunately, reduced blood flow along with oxidative stress may also appear in other 
pathological conditions, such as coronary heart diseases, cerebrovascular disease, inflam-
mation, hypertension, diabetes and atherosclerosis (9–12). These pathological conditions 
or their complications are usually associated with reduced nitric oxide activity (13–16).
animal experiments have demonstrated that free radical traps are effective against 
ischemia/reperfusion injuries. Nitrones are a class of effective spin traps used in experi-
mental biomedical research. These compounds have the ability to trap superoxide anion 
and hydroxyl radical, thus alleviating many of the toxic effects associated with radical 
formation, such as ischemia/reperfusion injuries (17), aging (18), lDl oxidation (19), ccl4-
induced liver injury (20), bacterial and viral infections (21), nerve degenerative conditions 
(22), death induced by buthylhydroxyperoxyde (23), drug induced diabetes and alcohol 
toxicity (24). Based on its radical trapping ability, one nitrone derivative (NXy-059) has 
been tested as a new drug in the anti-ischemic therapy in different phase-3 clinical trials 
(17).
We have previously demonstrated that nitrones are not only extraordinary spin traps, 
but they can also serve as nitric oxide sources in vitro. The formation of nitric oxide is self-
limiting and takes place via interaction of a nitrone with a free radical. Increasing the ni-
trone concentration leads to an asymptotic increase in the amount of the produced nitric 
oxide (25). Finding an effective nitric oxide donor that can act as a spin trap, releasing the 
vasodilating agent after a spin trapping reaction, could bring extraordinary benefits to the 
current vasodilating therapy. The release of nitric oxide in vitro from nitrones has already 
been reported in the literature (26, 27). Our goal is to demonstrate that the release of nitric 
oxide takes place in vivo as well.
eXPerIMeNTAl
All common chemicals and reagents (Nacl and kcl, chimopar, romania, Na2HPO4 
and kH2PO4, merck, Germany, DmSo, Sigma-aldrich, uSa; ethanol p. a. gradient-grade 
methanol for HPlc and gradient-grade acetonitrile for HPlc, Merck, were purchased 
from local providers and were used without further purification. ultra-pure water was 
obtained using a mili-Q purification system (millipore, uSa).
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In vitro release of nitric oxide from nitrones
The chemical name and structures of the tested nitrones are given in Fig. 1 and Table 



















































C-phenyl N-alkyl nitrone C-terephtal N-alkyl nitrone
C-glioxal N-alkyl nitrone Diphenyl nitrone
C-phenothiazine nitrone C-phenothiazone dinitrone
Fig. 1. chemical structures of the tested nitrones (r1 – r9: substituents given in Table I).
Table I. Chemical names and substituents of the studied substances
Abbreviation chemical name Substituent 
c-phenyl N-alkyl nitrones
PBN phenyl-N-tert-butylnitrone r1 = tert-butyl
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Abbreviation chemical name Substituent 
Diphenyl nitrone
DPN1 (Z)-N-(4-hydroxybenzylidene)aniline oxide r5 = 4-OH
DPN2 (Z)-4-chloro-N-(4-methoxybenzylidene)aniline oxide r4 = 4-cl, r5 = 4-OMe
DPN3 (Z)-4-bromo-N-(4-methoxybenzylidene)aniline oxide r4 = 4-Br, r5 = 4-OMe
DPN4 (Z)-4-chloro-N-(3,4-dimethoxybenzylidene)aniline oxide r4 = 4-cl, r5 = 3-OMe 
and 4-OMe
DPN5 (Z)-N-(4-methoxybenzylidene)aniline oxide r5 = 4-OMe
DPN6 (Z)-4-chloro-N-(3-chlorobenzylidene)aniline oxide r4 = 4-cl, r5 = 3-cl
DPN7 (Z)-N-(3-chlorobenzylidene)aniline oxide r5 = 3-cl
DPN8 (Z)-4-chloro-N-(4-hydroxybenzylidene)aniline oxide r4 = 4-cl, r5 = 4-OH
DPN9 (Z)-4-chloro-N-(3-hydroxybenzylidene)aniline oxide r4 = 4-cl, r5 = 3-OH
DPN10 (Z)-N-(4-chlorobenzylidene)aniline oxide r5 = 4-cl
DPN11 (Z)-N-(2-nitrobenzylidene)aniline oxide r5 = 2-NO2
DPN12 (Z)-4-chloro-N-(4-chlorobenzylidene)aniline oxide r4 = 4-cl, r5 = 4-cl
Phenothiazine mono- and dinitrones
PtzN1 (Z)-3-bromo-N-[(10-methyl-10H-phenothiazin-3-yl)methylene]
aniline oxide































Reaction of nitrones with hydroxyl radical in an aqueous environment under  
UV radiation
The apparatus, reagents and methods used for testing the nitric oxide releasing abil-
ity of nitrones under UV irradiation are described in detail in ref. 25. The experiments were 
performed at 20 °C. the following modifications were made: (i) sampling time and rate 
were reduced (0, 20, 40, 60, 120, 180 and 300 minutes), (ii) a new method was applied for 
detection of oxidation products of nitric oxide (nitrite and nitrate ions) (28), (iii) the solvent 
used to dissolve the nitrones was acetonitrile/water 1:1 (V/V).
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Interaction of nitrones with rat liver homogenate – preliminary testing
The following nitrones were tested during this experiment: PeN, DPN1, gIPN, TIPN, 
GtbN, ttbN, PbN, GSbN, tSbN, DPN11, DPN12, PtzN5, PtzN6, and PtzN7. the rat 
liver homogenate was prepared by homogenizing the liver of an adult male rat in 200 
mmol l–1 PbS buffer solution (NaCl 137 mmol l–1, kcl 2.7 mmol l–1, Na2HPO4 10 mmol l–1 
and kH2PO4 2 mmol l–1). in different test tubes, 3.5 mg of each tested nitrone was weighed 
and dissolved in 0.5 ml of dimethylsulfoxide (DmSo), then 7 ml of rat liver homogenate 
was added. the test tubes were immersed in a water bath at 37 °C. Samples were centri-
fuged at 3000 rpm and were analyzed using the literature method described in ref. 28.
Nitric oxide releasing ability of nitrones in vivo
eighteen rabbits (average body mass 4.62 ± 0.17 kg) were divided into two groups. each 
group consisted of nine individuals, eight for blood sampling and one for preliminary 
acute toxicity testing, which was important because many of the tested substances were 
not administered to animals before and literature data about their toxicity is unavailable. 
All animal experiments were carried out with institutional approval received from our 
university’s Committee on ethics and in accordance with international regulations.
Nitroglycerin (Ng) was not available as a pure substance. Thus nitroglycerin tablets 
containing 0.5 mg nitroglycerin per tablet (zentiva S.a., romania) were used. they were 
dissolved in the solvent, followed by filtration through a 0.5-mm filter.
The animals had food restriction for 16 hours before and during the experiment and 
free access to water. the first group of animals received PbN, GiPN, and tiPN. the second 
group received GSbN, GtbN, ttbN, DPN1 and sodium nitrite. both groups were admin-
istered blank (solvent) and nitroglycerin. after the administration of a substance or blank, 
animals were left to recover for two weeks. Doses and route of administration of the tested 
nitrones are summarized in Table II. The solvent used for dissolving/suspending the sub-
Table II. Substances, dosages and routes of administration
Substance Dose (mg kg–1) route of administration
Blank (solventa) 1.5 ml kg–1 Intravenously
Blank (solventa) 1.5 ml kg–1 Intraperitoneally
DPN1 100 Intraperitoneally
PBN 100 Intravenously
TIPN   70 Intraperitoneally
gIPN 100 Intraperitoneally
TTB 100 Intraperitoneally
GSb   50 Intraperitoneally
gTB   50 Intraperitoneally
Ng (positive control)        1.0 Intraperitoneally
                                    a Solvent: 20 % hydro-alcoholic solution
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stances for the in vivo administrations was 20 % hydroalcoholic solution. the nitrones, 
except for PBN, were administered as suspensions because of their poor solubility.
Blood was sampled from veins in the hind legs of the animals in anticoagulant-free 
test tubes. The reasons for using anticoagulant-free test tubes, blood preparation steps and 
the HPlC uV-ViS method for sample analysis are described in detail elsewhere (28). the 
limits of quantification of the HPlC uV-ViS method were low and none of the samples 
contained lower concentrations of analyte than these limits (0.2 mg ml–1 for nitrate and 2 
ng ml–1 for nitrite).
reSultS aND DiSCuSSioN
Nitric oxide release from nitrones after in vitro reaction with UV generated hydroxyl radical
Most of the alkyl nitrones and some diphenyl nitrones were more active in releasing 
nitric oxide than PbN (Fig. 2). in the case of the diphenyl nitrones, it is difficult to estimate 
the release of nitric oxide based on the concentrations of nitrite and nitrate (NOx), since a 
nitrite consuming process is taking place as described in reference (25). In some cases, this 
process leads to lower concentrations of nitrite in the solution of the nitrone than are those 
recorded for the blank. The total concentrations of NOx products and the percent of the 
nitrones that released nitric oxide are presented in Table III.
During the uV generated hydroxyl radical attack on the nitrones, we observed that 
terephtal dinitrones and glyoxal dinitrones were the most active releasers of nitric oxide 
and, compared to the rest of the nitrones, nitrite was present in higher amounts in these 
solutions at the end of the experiment than nitrate. This suggests that, in the presence of 
Fig. 2. changes in nitrite concentrations in the solution of TIPN and DPN11 (mean ± SD, n = 3).
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Table III. Concentration of NOx products and nitrone; percent of the nitrones that released NO 







Blank 1c 1.55 BlD – –
DPN1 0.31 7.25 2.347 0.26
DPN2 0.75 35.58 1.912 1.82
DPN3 1.06 10.17 1.634 0.59
DPN4 1.27 17.79 1.715 1.02
PBN 7.87 2.97 2.825 0.33
DPN5 0.58 9.68 2.203 0.40
DPN6 0.84 29.53 1.880 1.53
DPN7 1.80 15.05 2.160 0.71
DPN8 1.28 7.35 2.020 0.35
DPN9 1.08 22.82 2.020 1.11
Blank 2c 1.29 BlD – –
DPN10 2.18 15.16 2.160 0.73
DPN11 9.88 39.35 2.066 2.31
TIPN 144.79 24.82 2.128 7.90
TTBN 34.67 34.80 1.901 3.57
tSbN 44.39 52.17 1.901 5.00
DPN12 2.69 15.71 1.880 0.90
Blank 3c 0.79 BlD – –
PeN 27.84 2.03 3.030 0.96
gIPN 37.71 20.83 3.623 1.59
gTBN 38.20 44.83 3.012 2.73
GSbN 79.44 31.01 3.012 3.64
PtzN1 0.60 2.30 1.217 0.17
PtzN2 1.66 3.57 1.506 0.29
PtzN3 2.38 BlQ 1.337 0.12
PtzN4 11.19 11.67 1.109 2.06
PtzN5 11.99 4.02 0.876 1.74
PtzN6 5.45 2.24 0.956 0.72
PtzN7 9.37 8.01 1.761 0.94
PtzN8 0.25 BlQ 1.678 0.00
a measured after 5 hours of uV irradiation.
b Percent of molecules that released nitric oxide during 5 hours of UV irradiation (the corresponding blank was 
subtracted from the calculation of these results); a different blank was used for each series of nitrones kept under 
UV radiation.
c Blank: acetonitrile/water (1:1).
BlD – below limit of detection; BlQ – below limit of quantitation.
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these nitrones, nitric oxide may react directly with oxygen and water to form nitrite in-
stead of being oxidized to •NO2 (which in contact with water is expected to form equal 
amounts of nitrite and nitrate), or •NO2 reacts with •NO when N2O3 is formed; this com-
pound forms only nitrite when reacted with water. We proved earlier that in the conditions 
and duration of this experiment only minor amounts of nitrite are oxidized to nitrate (25). 
Therefore, in the cases when high nitrate and low nitrite concentrations were recorded, the 
oxidation of nitric oxide to nitrogen(V) (N2O5: source of nitrate alone) either took place in 
steps before the formation of nitrite, or the nitrone or one of its decomposition products 
induced an oxidative process of nitrite. The presence of nitrite in the blanks (acetonitrile 
and water in 1:1 ratio) is due to the fact that the nitrogen oxides migrate from the air into 
the samples. the concentration changes on a daily basis, being influenced by atmospheric 
conditions. Thus, for every series of tested substances a blank is required and the concen-
tration of nitrite in the blank should be subtracted from the results. However, concentra-
tions of nitrite in blanks are insignificant compared to those yielded by many nitrones.
Since there are no available in vivo test results assessing the formation of nitric oxide 
from nitrones, we used our in vitro test results to decide which nitrone should be admin-
istered to the animals. Although diphenyl nitrones did not prove to be active nitric oxide 
releasers during the in vitro experiment, we decided to test DPN1 in vivo, too. The reason 
was the intriguing nitrite-consuming process which, at least theoretically, might be pre-
ceded by a nitric oxide release.
Reaction of nitrones with rat liver homogenate
If the metabolism of nitrones to nitrite and nitrate takes place in the liver, the value of 
nitrones as nitric oxide donors will be considerably reduced. rat liver homogenate was 
used to verify if there were hepatic enzymes able to metabolize nitrones with release of 
nitric oxide. During the five-hour experiment, the concentration of nitrite from the blank 
sample (rat hepatic homogenate mixed with the solvent used in the case of nitrones) raised 
moderately in an asymptotic manner. only four nitrones (PeN, GtbN, tSbN, and PtzN7) 
were able to raise nitrite concentrations in the preliminary rat hepatic homogenate test. 
the other nitrones did not affect or even reduced nitrite concentrations compared to the 
blank. even those nitrones that proved to be very efficient in the hydroxyl radical test re-
duced significantly nitrite concentrations in the rat liver homogenate test (GiPN, ttbN, 
PbN, GSbN). Fig. 3 shows changes recorded for nitrite concentrations in the rat liver ho-
mogenate test in the case of PeN, PBN and blank. Nitrate concentrations were not changed 
by nitrones during this experiment.
our results show that there was no interaction between the efficient nitric oxide donors 
(gIPN and gTBN) and the rat hepatic homogenate regarding the formation of nitric oxide 
decomposition products, proving that the increase of NOx products observed during the 
in vivo experiment took place in the tissues and was not related to hepatic metabolism.
Animal response to blank and »positive blank«
Administration of a blank was done in order to observe changes in the blood concen-
tration of nitric oxide oxidation products brought by solvent administration. These 
changes, induced by blank administration, were used in the statistical evaluation of the 
modifications induced by the tested substances. Nitroglycerin was chosen as a »positive 
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blank«, a substance known to endogenously form nitric oxide. Nitroglycerin spectacularly 
increased the concentration of nitrite and nitrate in rabbit serum, showing that the animals 
reacted as expected to a nitric oxide donor.
Nitrogen oxide released by nitrones
Because of the need for repeated blood sampling, rabbits were chosen as experimental 
animals. The target dose of nitrones was 100 mg kg–1, the dose at which PBN and its re-
lated compounds showed effective spin trapping abilities in vivo (29). However, when signs 
of intense vasodilatation (tachycardia, tachypnea, reduced motor activity) were obvious 
during acute toxicity testing, a dose reduction to 70 or even 50 mg kg–1 was applied.
Table IV shows the nitrite and nitrate concentration increase/decrease caused by ni-
trones administered to the tested animals, along with their statistical significance. Nitrite 
was used as preferred NO marker, for the reasons presented in ref. 30.
gIPN was the most active nitric oxide releasing nitrone and increased all NOx values 
at all time intervals in a manner similar to nitroglycerin. A second increase in nitrite con-
centrations was noticed after 5 hours. in previous studies, GiPN and other similar nitrones 
showed biological effects that were attributed to nitric oxide release in vivo, but the authors 
were not able to prove the release, since only spontaneous in vitro decomposition was fol-
lowed (26). our results prove that these previously observed effects were indeed results of 
nitric oxide release from nitrones.
GtbN increased nitrite concentrations statistically significantly only at the 7-h sampl-
ing time (Fig. 4).
PbN, DPN1, GSbN and ttbN acted as nitric oxide modulators, significantly reducing 
nitrite concentrations, while tiPN had no effect on Nox concentrations. it is interesting to 
Fig. 3. changes in the rat hepatic homogenate nitrite concentrations brought by PeN (highest in-
crease) and PBN, compared to the blank (mean ± SD, n = 3).
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observe that many promising nitrones, even if they acted as active in vitro nitric oxide re-
leasers, proved to be the contrary when examined in vivo. An explanation might be their 
ability to interfere with NoS activity, so that an equilibrium is established between the 
ability to release nitric oxide and the ability to block the enzyme that normally produces it.
It is worth mentioning that, with the exception of DPN1, the administration of ni-
trones to animals was accompanied by signs of vasodilatation (tachycardia, dilated blood 
vessels in the ear, redness of the ear, easy blood sampling procedure). On the other hand, 
the nitrones that reduce significantly nitric oxide formation, such as DPN1, could also have 
therapeutic values since there are conditions (bacterial infection) in which nitric oxide is 
released in high amounts with unwanted effects.
in order to notice possible toxic effects of nitrones on the animals, food intake and 
body mass were monitored throughout the experiment. No signs of toxicity were observed 
during the administration of nitrones. the only observable effects were those related to 
the administration of substances with vasodilating activity but they were transient.





0.666 2 5 7
PBN
Nitrate     4.97         6.19*        8.98*
ND
Nitrite  –73.3*e  –38.1* –33.4
TIPN
Nitrate   –0.21     –0.63       0.30
ND
Nitrite  11.8   –3.2   32.7
gIPN
Nitrate       1.05*         1.20*         3.00*
ND
Nitrite   16.9*     12.8*    49.9*
TTBN
Nitrate    –0.74*        3.76*       0.87    –2.17
Nitrite –5.4   –26.7*   –7.0  –11.9*
GSbN
Nitrate       3.34*         3.40*       2.07    –0.55
Nitrite –28.7*   –41.1*   –21.1* –12.7
gTBN
Nitrate   –1.37         3.08*         1.60*    –0.99
Nitrite   3.9  –20.4   –1.8    42.8*
DPN1
Nitrate     11.18*         7.56*       1.71       1.01
Nitrite –81.0*  –114.2*  –83.9* –67.5
Ng
Nitrate       1.37*         1.97*        3.36*
ND
Nitrite   83.2*     37.3*    40.9*
a changes were calculated using the formula: [(TxN – T0N)–(TxB – T0B)], where TxN is concentration of nitrite or nitrate 
at a time point after nitrone administration; T0N = concentration of nitrite or nitrate before nitrone administration 
(zero time concentration for nitrone); TxB = concentration of nitrite or nitrate at a time point after blank administra-
tion; T0B = concentration of nitrite or nitrate before blank administration (zero time concentration for blank)
ND – not determined
b Nitrate concentration is given in mg ml–1.
c Nitrite concentration is given in ng ml–1.
* Statistically significant differences compared to negative blank (p < 0.05).
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Our research proved that nitrones can serve as important in vivo sources of nitric ox-
ide. However, we have to emphasize that generalization cannot be applied to this state-
ment since all nitrones acted to some extent as potential nitric oxide donors in vitro and 
only two were successfully proven as in vivo nitric oxide donors.
CoNCluSioNS
our findings suggest that nitrones can be considered useful for therapeutic purposes 
since they can release nitric oxide and possess an extraordinary spin trapping ability. This 
can be a very useful characteristic of a new class of vasodilating agents. Such agents will 
not only provide vital vasodilatation in the ischemic tissue but will also prevent the dam-
age brought about by the free radicals generated during reperfusion. The importance of 
hydroxyl radical in the formation of nitric oxide could even suggest that the targeted va-
sodilatation in the ischemic tissue might be provided. Further studies are needed to prove 
this claim.
Abbreviations, acronyms, symbols. – blD – below limit of detection; blQ – below limit of quantifica-
tion; DPN1 – (Z)-N-(4-hydroxybenzylidene)anilineoxide; DPN10 – (Z)-N-(4-chlorobenzylidene)anili-
ne oxide; DPN11 – (Z)-N-(2-nitrobenzylidene)aniline oxide; DPN12 – (Z)-4-chloro-N-(4-chlorobenzy-
lidene)aniline oxide; DPN2 – (Z)-4-chloro-N-(4-methoxybenzylidene)aniline oxide; DPN3 – (Z)-4-
bromo-N-(4-methoxybenzylidene)aniline oxide; DPN4 – (Z)-4-chloro-N-(3,4-dimethoxybenzylidene)
aniline oxide; DPN5 – (Z)-N-(4-methoxybenzylidene)aniline oxide; DPN6 – (Z)-4-chloro-N-(3-chloro-
benzylidene)aniline oxide; DPN7 – (Z)-N-(3-chlorobenzylidene)aniline oxide; DPN8 – (Z)-4-chloro-N-
(4-hydroxybenzylidene)aniline oxide; DPN9 – (Z)-4-chloro-N-(3-hydroxybenzylidene)aniline oxide; 
gIPN – (N,N’Z,N,N’Z)-N,N’-(ethane-1,2-diylidene)bis(propan-2-amine oxide); GSbN – (N,N‘Z,N,N‘Z)-
Fig. 4. Changes of nitrite concentrations compared to the blank after GiPN administration to animals 
(change in nitrite concentration was calculated by subtracting the concentration measured at time X 
from that measured at time 0).
424
M. D. croitoru et al.: Nitrones: not only extraordinary spin traps, but also good nitric oxide sources in vivo, Acta Pharm. 65 (2015) 
413–426.
 
N,N‘-(ethane-1,2-diylidene)bis(butan-2-amine oxide); gTBN – (N,N‘Z,N,N‘Z)-N,N‘-(ethane-1,2-diyli-
dene)bis(2-methylpropan-2-amine oxide); HPlc – high pressure liquid chromatography; lDl – low 
density lipoproteins; Ng – nitroglycerin; NOx – sum of nitrite and nitrate concentration; NXy-059 – 
disufenton sodium, a nitrone derivative; PBN – phenyltert-butylnitrone; PeN – phenyl-N-ethylnitrone; 
PtzN1 – (Z)-3 -bromo-N-((10-methyl-10H-phenothiazin-3-yl)methylene)aniline oxide; PtzN2 – (Z)-N-
((10-methyl-10H - -phenothiazin-3-yl)methylene)aniline oxide; PtzN3 – (Z)-3-acetyl-N-((10-methyl-
10H-phenothiazin-3-yl)methylene)aniline oxide; PtzN4 – (N,N’Z,N,N’Z)-N,N’-(10-methyl-10H-phe-
nothiazine-3,7-diyl)bis(methan-1-yl-1-ylidene)bis(aniline oxide); PtzN5 – (Z)-N-((10-octadecyl-10H-
phenothiazin-3-yl)methylene)aniline oxide; PtzN6 – (E)-N-((10-octedecyl-10H-phenothiazin-3-yl)
methylene)ethanamine oxide; PtzN7 – (E)-N-((10-ethyl-10H-phenothiazin-3-yl)methylene)methana-
mine oxide; PtzN8 – (E)-N-((10-ethyl-10H-phenothiazin-3-yl)methylene)ethanamine oxide; TIPN – 
(N,N’Z,N,N’Z)-N,N’-(1,4-phe nyl enebis(methanylylidene))bis(propan-2-amine oxide); tSbN – (N,N’Z, 
N,N’Z) -N,N’-(1,4-phenyl ene bis(methanylylidene))bis(butan-2-amine oxide); TTBN – (N,N’Z,N,N’Z)-
N,N’-(1,4-phenylenebis(methan-1-yl-1-ylidene))bis(2-methylpropan-2-amine oxide).
Acknowledgments. – This project was supported by the University of Medicine and Pharmacy of 
tîrgu mureş, internal grant number 30/11.12.2013.
reFereNCeS
  1.  J. ahn and J. kim, mechanisms and consequences of inflammatory signaling in the myocardium, 
Curr. Hypertens. Rep. 14 (2012) 510–516; DOI: 10.1007/s11906-012-0309-0.
  2.  D. M. Ansley and B. Wang, Oxidative stress and myocardial injury in the diabetic heart, J. Pathol. 
229 (2013) 232–241; DOI: 10.1002/path.4113.
  3.  a. m. Walters, G. a. Porter and P. S. brookes, mitochondria as a drug target in ischemic heart 
disease and cardiomyopathy, Circ. Res. 111 (2012) 1222–1236; Doi: 10.1161/CirCreSaHa.112.265660.
  4.  C. Sai and l. Shuzhuang, the Na+/ca2+ exchanger in cardiac ischemia/reperfusion injury, Med. 
Sci. Monit. 18 (2012) 161–165; Doi: 10.12659/mSm.883533.
  5.  J. m. Pilcher, P. Young, m. Weatherall, i. rahman, r. S. bonser and r. W. beasley, a systematic 
review and meta-analysis of the cardioprotective effects of remote ischaemic preconditioning in 
open cardiac surgery, J. R. Soc. Med. 105 (2012) 436–445; DOI: 10.1258/jrsm.2012.120049.
  6.  D. J. Hausenloy and D. m. Yellon, reperfusion injury salvage kinase signalling: taking a riSk for 
cardioprotection, Heart Fail. Rev. 12 (2007) 217–234; DOI: 10.1007/s10741-007-9026-1.
  7.  r. rodrigo, j. c. Prieto and r. castillo, cardioprotection against ischaemia/reperfusion by vita-
mins C and e plus n-3 fatty acids: molecular mechanisms and potential clinical applications, Clin. 
Sci. (lond). 124 (2013) 1–15; Doi: 10.1042/CS20110663.
  8.  r. rodrigo, J. Vinay, r. Castillo, m. Cereceda, r. asenjo and J. zamorano, use of vitamins C and 
e as a prophylactic therapy to prevent postoperative atrial fibrillation, Int. J. Cardiol. 138 (2010) 
221–228; Doi: 10.1016/j.ijcard.2009.04.043.
  9.  M. g. Andreassi, coronary atherosclerosis and somatic mutations: an overview of the contribu-
tive factors for oxidative DNA damage, Mutat. Res. 543 (2003) 67–86; Doi: 10.1016/S1383-5742 
(02)00089-3.
10.  H. a. kim, a. a. miller, G. r. Drummond, a. G. thrift, t. V. arumugam and t. G. Phan, Vascular 
cognitive impairment and Alzheimer’s disease: role of cerebral hypoperfusion and oxidative 
stress, Naunyn-Schmiedeberg. Arch. Pharmacol. 385 (2012) 953–959; DOI: 10.1007/s00210-012-0790-7.
11.  l. kuo, N. Thengchaisri and T. W. Hein, regulation of coronary vasomotor function by reactive 
oxygen species, Mol. Med. Ther. 1 (2012) 1–4; DOI: 10.4172/2324-8769.1000101.
425
M. D. croitoru et al.: Nitrones: not only extraordinary spin traps, but also good nitric oxide sources in vivo, Acta Pharm. 65 (2015) 
413–426.
 
12.  a. S. Simon, V. Chithra, a. Vijayan, r. D. Dinesh and t. Vijayakumar, altered DNa repair, oxida-
tive stress and antioxidant status in coronary artery disease, J. Biosci. 38 (2013) 385–389; DOI: 
10.1007/s12038-013-9313-z.
13.  e. bor-Seng-Shu, W. S. kita, e. G. Figueiredo, W. S. Paiva, e. t. Fonoff, m. J. teixeira and r. b. Pan-
erai, cerebral hemodynamics: concepts of clinical importance, Arq. Neuropsiquiatr. 70 (2012) 352–
356.
14.  F. Folli, D. corradi, P. Fanti, A. Davalli, A. Paez and A. giaccari, The role of oxidative stress in the 
pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a 
mechanistic-based therapeutic approach, Curr. Diabetes Rev. 7 (2011) 313–324; DOI: 10.2174/ 
157339911797415585.
15.  N. A. Terpolilli, M. A. Moskowitz and N. Plesnila, Nitric oxide: considerations for the treatment 
of ischemic stroke, J. Cereb. Blood Flow Metab. 32 (2012) 1332–1346; DOI: 10.1038/jcbfm.2012.12.
16.  N. Toda and H. Toda, coronary hemodynamic regulation by nitric oxide in experimental animals: 
recent advances, Eur. J. Pharmacol. 667 (2011) 41–49; DOI: 10.1016/j.ejphar.2011.06.028.
17.  m. r. macleod, H. b. van der Worp, e. S. Sena, D. W. Howells, u. Dirnagl and G. a. Donnan, evi-
dence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study 
quality, Stroke 39 (2008) 2824–2829; Doi: 10.1161/StrokeaHa.108.515957.
18.  r. A. Floyd, k. Hensley, M. j. Forster, j. A. kelleher-Anderson and P. l. Wood, Nitrones as neuro-
protectans and antiaging drugs, Ann. N. Y. Acad. Sci. 959 (2002) 321–329; DOI: 10.1111/j.1749-6632.2002.
19.  b. kalyanaraman, J. Joseph and S. Parthasarathy, the spin trap, alpha-phenyl N-tert-butylnitrone, 
inhibits the oxidative modification of low density lipoprotein, FEBS. Lett. 280 (1991) 17–20; DOI: 
10.1016/0014-5793(91)80194-8.
20.  e. G. Janzen, r. a. towner and S. Yamashiro, the effect of phenyl tert-butyl nitrone (PbN) on 
ccl4-induced rat liver injury detected by proton magnetic resonance imaging (MrI) in vivo and 
electron microscopy (eM), Free Radic. Res. Commun. 9 (1990) 325–335; DOI: 10.3109/10715769009145691.
21.  m. thirumalaikumar, S. Sivakolunthu, S. muthusubramanian, P. mohan and S. Sivasubramanian, 
Synthesis, characterization and antimicrobial studies of metal (ii) bis-chelates and mixed-ligand 
complexes of alpha-(2-hydroxyphenyl)-N-(1-phenyl-2-nitroethyl)nitrone, Boll. Chim. Farm. 35 
(1999) 207–210.
22.  k. T. knecht and r. P. Mason, In vivo spin trapping of xenobiotic free radical metabolites, Arch. 
Biochem. Biophys. 303 (1993) 185–194; DOI: 10.1006/abbi.1993.1272.
23.  S. kuroda, r. tsuchidate, m. l. Smith, k. r. maples and b. k. Siesjo, Neuroprotective effects of a 
novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat, J. Cereb. Blood Flow Metab. 
9 (1999) 623–625; DOI: 10.1097/00004647-199907000-00008.
24.  l. A. reinke, D. r. Moore, c. M. Hague and P. B. Mccay, Metabolism of ethanol to 1-hydroxy-
ethyl radicals in rat liver microsomes: comparative studies with three spin trapping agents, Free 
Radic. Res. 21 (1994) 213–222; DOI: 10.3109/10715769409056573.
25.  m. D. Croitoru, i. Fülöp, m. C. Pop, t. Dergez, b. mitroi, m. t. Dogaru and b. tőkés, Nitrones are 
able to release nitric oxide in aqueous environment under hydroxyl free radical attack, Nitric oxide 
25 (2011) 309–315; DOI: 10.1016/j.niox.2011.05.007.
26.  r. camehn and k. rehse, New NO donors with antithrombotic and vasodilating activities, N-(1-
cyanocyclohexyl)-c-phenylnitrones and glyoxaldinitones, Arch. Pharm. Pharm. Med. Chem. 333 
(2000) 130–134; Doi: 10.1002/(SiCi)1521-4184(20005)333:53.0.Co;2-D.
27.  W. Chamulitrat, S. J. Jordant, r. P. mason, k. Saito and r. G. Cutler, Nitric oxide formation during 
light-induced decomposition of phenyl-N-tert-butylnitrone, J. Biol. Chem. 268 (1993) 11520–11527.
28.  M. D. croitoru, Nitrite and nitrate can be accurately measured in vegetal and animal samples 
using an HPlC-uV/ViS technique, J. Chromatogr. B 911 (2012) 154–161; DOI: 10.1016/j.jchromb. 
2012.11.006.
426
M. D. croitoru et al.: Nitrones: not only extraordinary spin traps, but also good nitric oxide sources in vivo, Acta Pharm. 65 (2015) 
413–426.
 
29.  P. a. lapchak, D. F. Chapman and J. a. zivin, Pharmacological effects of the spin trap agents N-t-
butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TeMPO) in a rabbit throm-
boembolic stroke model: combination studies with the thrombolytic tissue plasminogen activa-
tor, Stroke 32 (2001) 147–153; Doi: 10.1161/01.Str.32.1.147.
30.  M. D. croitoru, I. Fülöp, e. Fogarasi and D. l. Muntean, Is nitrate a good biomarker of the nitric 
oxide status?, Rev. Romana Med. Lab. 23 (2015) 127–136; DOI: 10.1515/rrlm-2015-0001.
